EyePoint Pharmaceuticals, Inc.
Company Name | EyePoint Pharmaceuticals, Inc. |
Stock Symbol | EYPT |
On August 30, 2022, after market hours, EyePoint disclosed that it had received a subpoena from the U.S. Attorney's Office for the District of Massachusetts seeking documents regarding sales practices for its postoperative inflammation treatment, DEXYCU.
On this news, EyePoint’s stock fell as much as 20% during after-hours trading on August 30, 2022, thereby injuring investors.
Submit Your Information
If you suffered a loss on your EyePoint Pharmaceuticals, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.